Health Alert: Novo Nordisk's blockbuster weight loss drug, Wegovy, may be prescribed to reduce heart attack risk in overweight people, FDA says

The drug has the same active ingredient as the company's diabetes drug, Ozempic. The approval is based on research showing that Wegovy reduced the risk of major cardiovascular events such as heart attacks and strokes by 20 percent, compared with a placebo. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

Sign up for alerts Health Alert March 8, 2:29 p.m. EST Novo Nordisk's blockbuster weight loss drug, Wegovy, may be prescribed to reduce heart attack risk in overweight people, FDA says The drug has the same active ingredient as the company's diabetes drug, Ozempic. The approval is based on research showing that Wegovy reduced the risk of major cardiovascular events such as heart attacks and strokes by 20 percent, compared with a placebo. Read more   Advertisement

Manage my email newsletters and alerts | Unsubscribe | Privacy Policy | Help You received this email because you signed up for news alerts or because it is included in your subscription. ©2024 The Washington Post | 1301 K St NW, Washington DC 20071